Data from Pharmawand - Curated by Toby Galbraith - Date added 08 November 2012

The FDA has cleared Acessa, from Halt Medical, a new medical system for treating Uterine Fibroids. To ablate targeted fibroids, the Acessa System delivers monopolar radiofrequency energy to tissue through a disposable electrosurgical RF handpiece. After treatment, the fibroid is re-absorbed by the surrounding tissue. Using this laparoscopic, outpatient procedure, the physician can provide a treatment that is low risk to the patient. By treating all of the fibroids, the risk of the symptom recurrence is low.

Two clinical studies have been published recently that demonstrate the effectiveness of the Acessa System for the treatment of Uterine Fibroids in 69 women aged 28 - 51. These two studies evaluated the pre-operative and post-operative reduction in symptom severity and improvement in quality of life for the patients who underwent treatment. Both studies demonstrated that symptom severity for symptomatic uterine fibroids was significantly reduced and the patients’ quality of life significantly improved post treatment.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breast Cancer

Learn about the pathophysiology, diagnosis, molecular subtypes and treatment of breast cancer, including specific focus on HR+ aggressive disease

Visit Breast Cancer

Chronic Spontaneous Urticaria

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria

Related Content